PMID- 7752828
OWN - NLM
STAT- MEDLINE
DCOM- 19950621
LR  - 20191031
IS  - 0098-2997 (Print)
IS  - 0098-2997 (Linking)
VI  - 15 Suppl
DP  - 1994
TI  - Usefulness of coenzyme Q10 in clinical cardiology: a long-term study.
PG  - s165-75
AB  - Over an eight year period (1985-1993), we treated 424 patients with various forms 
      of cardiovascular disease by adding coenzyme Q10 (CoQ10) to their medical 
      regimens. Doses of CoQ10 ranged from 75 to 600 mg/day by mouth (average 242 mg). 
      Treatment was primarily guided by the patient's clinical response. In many 
      instances, CoQ10 levels were employed with the aim of producing a whole blood 
      level greater than or equal to 2.10 micrograms/ml (average 2.92 micrograms/ml, n 
      = 297). Patients were followed for an average of 17.8 months, with a total 
      accumulation of 632 patient years. Eleven patients were omitted from this study: 
      10 due to non-compliance and one who experienced nausea. Eighteen deaths occurred 
      during the study period with 10 attributable to cardiac causes. Patients were 
      divided into six diagnostic categories: ischemic cardiomyopathy (ICM), dilated 
      cardiomyopathy (DCM), primary diastolic dysfunction (PDD), hypertension (HTN), 
      mitral valve prolapse (MVP) and valvular heart disease (VHD). For the entire 
      group and for each diagnostic category, we evaluated clinical response according 
      to the New York Heart Association (NYHA) functional scale, and found significant 
      improvement. Of 424 patients, 58 per cent improved by one NYHA class, 28% by two 
      classes and 1.2% by three classes. A statistically significant improvement in 
      myocardial function was documented using the following echocardiographic 
      parameters: left ventricular wall thickness, mitral valve inflow slope and 
      fractional shortening. Before treatment with CoQ10, most patients were taking 
      from one to five cardiac medications. During this study, overall medication 
      requirements dropped considerably: 43% stopped between one and three drugs. Only 
      6% of the patients required the addition of one drug. No apparent side effects 
      from CoQ10 treatment were noted other than a single case of transient nausea. In 
      conclusion, CoQ10 is a safe and effective adjunctive treatment for a broad range 
      of cardiovascular diseases, producing gratifying clinical responses while easing 
      the medical and financial burden of multidrug therapy.
FAU - Langsjoen, H
AU  - Langsjoen H
AD  - University of Texas Medical Branch, Galveston 77551, USA.
FAU - Langsjoen, P
AU  - Langsjoen P
FAU - Langsjoen, P
AU  - Langsjoen P
FAU - Willis, R
AU  - Willis R
FAU - Folkers, K
AU  - Folkers K
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Mol Aspects Med
JT  - Molecular aspects of medicine
JID - 7603128
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Coenzymes)
RN  - 1339-63-5 (Ubiquinone)
RN  - EJ27X76M46 (coenzyme Q10)
SB  - IM
MH  - Cardiomyopathy, Dilated/drug therapy
MH  - Cardiovascular Agents/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy/mortality
MH  - Coenzymes
MH  - Diastole
MH  - Drug Therapy, Combination
MH  - Echocardiography
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Function Tests
MH  - Heart Valve Diseases/drug therapy
MH  - Humans
MH  - Hypertension/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Prolapse/drug therapy
MH  - Myocardial Ischemia/drug therapy
MH  - Treatment Outcome
MH  - Ubiquinone/*analogs & derivatives/therapeutic use
EDAT- 1994/01/01 00:00
MHDA- 1994/01/01 00:01
CRDT- 1994/01/01 00:00
PHST- 1994/01/01 00:00 [pubmed]
PHST- 1994/01/01 00:01 [medline]
PHST- 1994/01/01 00:00 [entrez]
AID - 0098-2997(94)90026-4 [pii]
AID - 10.1016/0098-2997(94)90026-4 [doi]
PST - ppublish
SO  - Mol Aspects Med. 1994;15 Suppl:s165-75. doi: 10.1016/0098-2997(94)90026-4.